sahinozgur

We participated in the AACR conference with three distinct poster presentations.

Ozgur Sahin was recognized for his work and article, “Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer,” published by Nature Communications Nov. 2, 2023. https://medicine.musc.edu/research/excellence-awards

https://hollingscancercenter.musc.edu/news/archive/2024/02/06/hollings-researchers-demonstrate-restoring-effectiveness-of-breast-cancer-drug-after-resistance

We are thrilled to share the news that Ozge, our PhD candidate, has successfully defended her thesis entitled “Targeted Multimodal Approaches to Treat Aggressive Breast Cancers via Therapeutic Inhibition of Key Vulnerabilities.” Her completion of the PhD program is distinguished by a noteworthy contribution of high-impact papers in the field. Read more…

We participated in the Drug Discovery and Development Retreat organized by MUSC and USC. During the event, we had the opportunity to engage with numerous presentations on translational cancer research, including Dr. Sahin’s insightful talk on “From mechanism of resistance to drug discovery: Targeting the most aggressive breast cancers.” Members Read more…

Our postdoctoral researcher, Metin, has been awarded the prestigious Hollings Postdoctoral Fellowship —a well-deserved recognition of his outstanding work.

On November 4th, the Sahin Lab embarked on a remarkable journey, cycling 10 miles to raise awareness for cancer in LOWVELO. The ride exemplified the profound impact that collective action can have in spreading awareness and advancing the cancer research and support.

https://hollingscancercenter.musc.edu/news/archive/2023/11/02/hollings-researchers-uncover-new-targets-for-breast-cancers-resistant-to-standard-therapies

With the title of “Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer”.